Piramal Pharma Limited Announces Results for Q1 FY27
Piramal Pharma Limited reported strong financial results for Q1 FY27, citing mid-to-high teens revenue growth across its business segments. The company plans to continue its momentum through disciplined brand investments and expansion in complex hospital generics.
Why it matters
The company's performance reflects broader trends in the Indian pharmaceutical sector, particularly in contract manufacturing and consumer healthcare growth.
MUMBAI, India , July 29, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the First Quarter (Q1) ended 30 th June 2026.
Note: Exceptional items in Q1FY26 include one-time insolvency proceeds received from a claim filed against a third-party supplier of our complex hospital generics business, with the NCLT in November 2023
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in